Prevalence of Precancerous Lesions Based on Digital Cervicography with VIA/VILI among Women Positive for High-Risk Human Papillomavirus Serotypes: A Screening Center-Based Study in Cameroon

Background: Since 2021, high-risk Human Papilloma Virus (HR-HPV) testing has been the recommended screening test for cervical cancer for all settings;either used alone in a “test and treat” strategy, or with a triage test, with or without biopsy, before treatment. Cameroon has rolled out immunization against HPV 16 and 18, but studies show a higher prevalence of non-16/18 HR-HPV types. Objectives: Determine the prevalence of precancerous lesions, in women with HR-HPV infection and evaluate association of digital cervicography (DC) VIA/VILI positivity with HPV serotype, as a measure of their contribution to precancer and cancer incidence. Methodology: The study was cross-sectional, descriptive, and analytic. It took place at the Etoug-Ebe and Ekoudoum Baptist Hospitals in Yaoundé, during the period April-September 2022. We reviewed the records of women screened for cervical cancer between February 2020 and December 2021 and evaluated the prevalence of lesions on digital cervicography (DC) with VIA/VILI for women positive for HR-HPV serotypes. The data were analyzed using SPSS version 20.0 for Windows. P values Results: We identified 315 cases with a positive HR-HPV deoxyribonucleic acid (DNA) test, 224 (71.1%) had a DC VIA/VILI triage test done. Of these, 30 (13.4%) women had a positive DC VIA/VILI, with five women (2.2%) having lesions suggestive of cancer. Out of 11 cases positive for HPV 16 alone, 05 (45.5%) had a positive DC VIA/VILI test. Of the 14 cases positive for HPV 18 alone, 03 (21.4%) had a positive VIA/VILI, meanwhile only 19 (10.7%) of the 177 cases positive for non-16/18 HPV had a positive VIA/VILI test. Conclusion: A high proportion of women (13.4%) with HR HPV had a positive DC VIA/VILI, with a significant proportion (2.2%) having lesions suggestive of invasive cervical cancer HR-HPV serotype was associated with DC VIA/VILI positivity;HPV 16 had the strongest association (45.5%), followed by HPV 18 (21.4%), and non-16/18 HR-HPV (10.7%), suggesting a decreasing order of oncogenicity.

Distribution of High-Risk Human Papillomavirus Genotypes among Women with Colposcopic Diagnosis of Cervical Intraepithelial Neoplasia in Bangladesh

Background: The incidence of cervical cancer is high in Bangladesh and there is a high prevalence of preinvasive lower genital tract disease among women of reproductive age. Persistent high-risk Human Papilloma Virus (HPV) infection is the main underlying cause of cervical cancer and its precursor, cervical intraepithelial neoplasia (CIN). Objective: The aim of the study was to identify the subtypes of high-risk HPV infection among women with the colposcopic diagnosis of cervical intraepithelial neoplasia in Bangladesh. Methods: This cross-sectional observational study was conducted in the colposcopy clinic of Dhaka Medical College Hospital over a six-month period. A total of 100 participants were enrolled. Married women, between 30 - 60 years of age with colposcopically diagnosed cervical intra epithelial neoplasia were enrolled. Women with chronic illness, pregnancy, and women unable to consent were excluded from this study. After counselling, colposcopically directed punch biopsies were taken from each CIN case concurrently with high-risk HPV testing by polymerase chain reaction (PCR). Results: The mean age of the patients was 38.69 (SD ±7.76) years. CIN 1 was diagnosed in 57% of participants, while 24% had CIN II and 19% had CIN III lesions. High-risk HPV was present in 52 patients. HPV 16 was the most common identified in 28 (53.84%) and HPV 18 was the second most common with 20 (38.46%) either singly or in combination with other high-risk subtypes. The other HPV strains, HPV 31, 33, 35, 52, 56 and 58, were also detected either as mono or co-infections. Out of the 52 HPV positive cases, 29 (55.8%) had mono infection and 23 (44.2%) had co-infection with several subtypes. The highest incidence (50%) of oncogenic HPV infections was present among women aged 35 - 45 years. Risk factors associated with HPV positive cases were high parity (P 0.05), early age at marriage (P = 0.754) and early age of first child. Conclusion: This study identified a high prevalence of HPV 16 and 18 genotypes. HPV vaccination with the current 9-valent HPV vaccine, which contains HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. Will be an effective public health measure to eradicate cervical cancer in Bangladesh.

Rapid detection of high-risk HPV16 and HPV18 based on microchip electrophoresis

Researches on detection of human papillomavirus(HPV)high-risk samples were carried out by polymerase chain reaction(PCR)coupled with microchip electrophoresis(MCE).Herein,we introduced a simple,rapid,automated method for detecting high-risk samples HPV16 and HPV18.In this research,general primers were initially selected to obtain sufficient detectable yield by PCR to verify feasibility of MCM method for HPV detection,then type-specific primers were further used to evaluate the specificity of MCE method.The results indicated MCE method was capable of specifically detecting high-risk HPV16 and HPV18,and also enabled simultaneous detection of multiplex samples.This MCE method described here has been successfully applied to HPV detection and displayed excellent reliability demonstrating by sequencing results.The inherent capability of MCE facilitated HPV detection conducted in a small chip with automated,high throughput,massive parallelized analysis.We envision that MCE method will definitely pave a way for clinical diagnosis,and even on-site screening of cervical cancer.

Human papillomavirus-associated diseases and cancers

Human papillomaviruses(HPVs) have been detected in cervical cancer cells and skin papilloma cells, which have a variety of types, including low-risk and high-risk types. HPV genome replication requires the host cell's DNA synthesis machinery, and HPVs encode proteins that maintain differentiated epithelial cells in a replication-competent state. HPV types are tissue-specific and generally produce different types of lesions, either benign or malignant. This review examines different HPV types and their associated diseases and presents therapeutic options for the treatment of HPV-positive diseases.

Efficacy of 2LPAPI®, a Micro-Immunotherapy Drug, in Patients with High-Risk Papillomavirus Genital Infection

Human papillomaviruses (HPVs) are well known for being linked to the development of cervical cancers, most of them being caused by the high-risk (HR) oncogenic genotypes, mainly 16 and 18. The efficacy of 2LPAPI® (Labo’Life), a micro-immunotherapy homeopathic drug, has been evaluated in HR-HPV infected women (n = 18), in a private gynecology practice, by comparing them to an untreated control group (n = 18). Patients were 20 to 45 years old and had cytology with Atypical Squamous Cells of Undetermined Significance (ASCUS) or Low grade Superficial Intra Lesions/ Cervical Intraepithelial Neoplasia Grade I (LSIL/CINI). Patients freely chose to be treated with the drug or not. Those deciding not to take the drug remained untreated and were followed as a control group. The drug was taken at the regimen of one capsule per day during 6 months. HR-HPV and cytology were evaluated at 6 and 12 months. After 12 months, HR-HPV was cleared in 78% of the patients taking the drug versus 44% in those not taking it (p = 0.086). In patients over 25 years, HR-HPV clearance in the treated group was significantly higher (81.3%) than in the control group (20%) (p = 0.004). The difference in the regression of the lesion grades almost reached statistical significance (p = 0.053). This follow-up confirms that the micro-immunotherapy drug 2LPAPI® is a safe and effective therapeutic approach to treat HR-HPV cervical lesions in women over 25 years.

Clinical significance of extended high-risk human papillomavirus genotyping and viral load in cervical cancer and precancerous lesions

Persistent infections with specific high-risk human papillomavirus(HR-HPV)strains are the leading cause of cervical cancer and precancerous lesions.HPV-16 and HPV-18 are associated with more than 70%of cervical cancer.However,with recent widespread vaccination efforts against cervical cancer,the infection rates of HPV-16 and HPV-18 have decreased across all age groups,while the infection rates of other HR-HPV strains have increased.The non-16/18 HR-HPV strains play an important role in cervical lesions.These strains can be identified with extended genotyping,and the 2019 American Society for Colposcopy and Cervical Pathology(ASCCP)guidelines recommended an HPV-based testing to assess the risk of cervical disease in patients.We reviewed and analyzed the clinical benefits of applying extended HR-HPV genotyping,which was published by the International Agency for Research on Cancer(HPV-16,18,31,33,35,39,45,51,52,56,58,59,66,and 68),to cervical cancer screening.This review concluded that cervical cancer screening needs to include extended HR-HPV genotyping.The examination of extended HR-HPV genotyping in cervical intraepithelial lesions and cervical cancers can help guide clinical practices.

人乳头瘤病毒L1基因分型国家参考品的升级换代研制

目的 对人乳头瘤病毒(HPV)L1基因分型国家参考品升级换代,以提高基于L1检测靶区的HPV核酸(分型)试剂的质量。方法 研制包含了34种不同型别HPV L1的质粒样品。经商业化核酸检测试剂复核验证,分装组成国家参考品。采用荧光PCR法进行量值标定,并溯源至WHO第一代HPV16 DNA国际参考品。结合不同实验室的协作标定研究和适用性验证结果,确定参考品的质量标准,并进一步考察参考品的稳定性。结果 国家参考品包括34种不同型别HPV样本和5种HPV阴性病原体,型别上囊括了HPV68a和HPV68b亚型。34种不同型别HPV DNA含量为6.26~7.08 Log10 IU/mL,并要求各试剂准确性应能检出其检测范围内的所有型别且分型正确,其检出限应不高于104 IU/反应。结论 成功建立了新一代HPV L1基因分型国家参考品,用于评价L1检测靶区的HPV核酸检测试剂的质量。

HPV检测联合液基薄层细胞学检测宫颈癌的诊断价值分析

目的 研究液基薄层细胞学(Thinprep-Cytologic Test, TCT)检测联合人乳头瘤病者(Human Papillomavirus, HPV)检测对宫颈癌的诊断价值。方法 选取2022年1月—2023年10月淄博市妇幼保健院新院区检验科的100例疑似宫颈癌前病变患者为研究对象,均实施HPV检测、TCT以及联合检测,以阴道镜下取宫颈活检病理诊断结果为金标准,分析上述单一及联合检测的阳性率以及诊断价值。结果 100例受检者中,HPV检查阳性检出率为20.00%,TCT阳性检出率为27.00%,TCT+HPV阳性检出率为35.00%;TCT+HPV的准确度(96.00%)、灵敏度(91.89%)高于TCT和HPV,差异有统计学意义(χ^(2)=8.000、15.457、7.974、18.231,P均<0.05)。结论 TCT+HPV具有较高的特异度、灵敏度及准确度,在宫颈癌诊断中具有积极意义。

Detection of human papillomavirus in oropharyngeal squamous cell carcinoma

Worldwide there has been a significant increase in the incidence of oropharyngeal squamous cell carcinoma(OPSCC)etiologically attributed to oncogenic human papillomavirus(HPV).Reliable and accurate identification and detection tools are important as the incidence of HPV-related cancer is on the rise.Several HPV detection methods for OPSCC have been developed and each has its own advantages and disadvantages in regard to sensitivity,specificity,and technical difficulty.This review summarizes our current knowledge of molecular methods for detecting HPV in OPSCC,including HPV DNA/RNA polymerase chain reaction(PCR),loop-mediated isothermal amplification(LAMP),p16 immunohistochemistry(IHC),and DNA/RNA in situ hybridization(ISH)assays.This summary may facilitate the selection of a suitable method for detecting HPV infection,and therefore may help in the early diagnosis of HPV-related carcinoma to reduce its mortality,incidence,and morbidity.

DETECTION OF HUMAN PAPILLOMAVIRUS TYPES 16, 18 DNA RELATED SEQUENCES IN BRONCHOGENIC CARCINOMA BY POLYMERASE CHAIN REACTION

In studying the relationship between human papillomavirus (HPV) and bronchogenic carcinoma, 'high-risk' HPV 16, 18 DNA sequences were detected in samples from 50 lung cancer patients, 18 patients with benign pulmonary diseases and 4 fetal lung tissues by polymerase chain reaction (PCR) and dot-blot hybridization with biotin-labelled probes. The results showed that HPV 16, 18 DNA related sequences were found in 32% of lung cancer specimens, with 10 cases of HPV 16, 5 cases of HPV 18 and 1 case of both types. 48.15% (13 / 27) of squamous cell carcinomas were shown to be positive for HPV 16, 18 DNA. In addition, two adenocarcinomas and one small cell carcinoma were positive for HPV 16 DNA. No specimens from benign diseases tissues and fetal lung tissues showed positive results. These results suggest that primary bronchogenic carcinoma is related to HPV infection.

人乳头瘤病毒检查、液基薄层细胞检测联合阴道镜检查在早期宫颈病变筛查中的意义

目的探讨人乳头瘤病毒检查、液基薄层细胞检测联合阴道镜检查在早期宫颈病变筛查中的运用效果。方法选取110例疑似宫颈病变患者为研究对象,均接受人乳头瘤病毒检查、液基薄层细胞检测与阴道镜检查,以病理诊断结果为金标准,比较人乳头瘤病毒检查、液基薄层细胞检测及阴道镜检查与联合检查的阳性检出情况,以及单独检查与联合检查的诊断效能。结果病理诊断确诊低度鳞状上皮内病变24例、高度鳞状上皮内病变33例与宫颈癌12例;联合检查的阳性检出率为98.55%,高于人乳头瘤病毒检查、液基薄层细胞检测及阴道镜检查的84.06%、62.32%、86.96%(P<0.05);联合检查的准确率、敏感度、特异度、阳性预测值与阴性预测值高于人乳头瘤病毒检查、液基薄层细胞检测及阴道镜检查(P<0.05)。结论在早期宫颈病变诊断中运用人乳头瘤病毒检查、液基薄层细胞检测联合阴道镜检查,能够明显提高阳性检出率,且具有较高的诊断效能,值得推广。

北京某三甲医院健康体检女性HPV感染情况及TCT结果分析

目的探讨北京某三甲医院健康体检女性HPV感染情况及TCT结果分析,为本地区宫颈癌防治提供参考。方法回顾分析2022年7月至2023年9月于中日友好医院进行健康体检的10124例女性HPV及TCT结果。结果健康体检女性10124例中,HPV阳性率为7.34%,不同年龄段间HPV阳性率比较差异具有统计学意义(χ^(2)=29.721,P<0.001)。高危型HPV占比前五位亚型是HPV⁃52、HPV⁃58、HPV⁃51、HPV⁃16和HPV⁃39。TCT结果阳性率为2.49%,≥61岁人群ASC和HSIL占比最高,21~岁人群LSIL组占比最高。随着宫颈病变加重,从ASC到LSIL再到HSIL,HPV的阳性率逐渐升高(51.41%,70.18%,88.89%),不同程度宫颈病变的HPV阳性率比较差异具有统计学意义(χ^(2)=485.453,P<0.001),不同程度宫颈病变之间HPV感染类型比较差异有统计学意义(χ^(2)=18.943,P<0.001)。结论宫颈病变程度加重,HPV感染率升高,应重视本地区适龄妇女宫颈癌筛查。

宫颈病变筛查中p16/mcm2、HPV检测的临床价值

目的:检测宫颈病变中宫颈脱落细胞p16/微小染色体维持蛋白(mcm2)的表达,探讨p16/mcm2与人乳头瘤病毒(HPV)检测在宫颈病变筛查的临床价值。方法:选取2023年5-10月在徐州市肿瘤医院妇科门诊或病房行宫颈癌筛查并符合入组标准的1045例女性,均行p16/mcm2免疫细胞化学双染检测及HPV检测,对p16/mcm2双染确诊为不明意义的非典型鳞状上皮细胞(ASC-US)及以上病变或HPV16/18阳性者行阴道镜检查、活检宫颈组织送病理检查。结果:p16/mcm2阳性率在HPV阴性组、低危HPV组、其他12种HPV阳性组和HPV16/18阳性组依次递增(P=0.000);p16/mcm2阳性表达在其他12种HPV阳性组和HPV16/18阳性组均高于HPV阴性组[OR=4.28(95%CI 2.02~9.04)、OR=76.64(95%CI 36.05~162.93)],在HPV16/18阳性组均高于其他12种HPV阳性组,且随宫颈病变程度加重p16/mcm2阳性表达增高(均P<0.05)。p16/mcm2检测筛查子宫颈上皮内瘤病变CIN1级、CIN2级和CIN3级的灵敏度和阳性预测值(85.0%、89.1%、94.3%,94.1%、97.0%、97.0%)均高于HPV。结论:p16/mcm2双染和HPV存在相关性,两者均可用于宫颈病变筛查;与HPV检测相比,p16/mcm2双染有较高灵敏度和阳性预测,p16/mcm2双染联合HPV检测有望成为有较好应用前景的宫颈癌筛查方案。

宫颈液基细胞学检查和人乳头瘤病毒检测与宫颈活检组织病理学诊断的关系

目的分析宫颈液基细胞学检查(TCT)、人乳头瘤病毒(HPV)检测与宫颈活检组织病理学诊断的关系。方法选取2020年1月—2023年6月本院收治的100例宫颈病变患者为研究对象,所有患者均行TCT检查、HPV检测及宫颈活检组织病理学检查,以病理学检查为金标准,评价TCT检查、HPV检测、TCT检查联合HPV检测的诊断价值。结果100例患者经宫颈活检组织病理学检查确诊为宫颈炎症30例、宫颈上皮内瘤变(CIN)Ⅰ20例、CINⅡ18例、CINⅢ14例、宫颈癌18例;TCT检查结果为非典型鳞状上皮细胞(ASC-US)37例、低度鳞状上皮内病变(LSIL)23例、高度鳞状上皮内病变(HSIL)22例、宫颈癌18例;HPV检测结果为阴性40例,阳性60例;TCT检查联合HPV检测结果为阴性31例,阳性69例。TCT检查联合HPV检测的敏感性、特异性与准确性明显高于单独进行TCT检查和HPV检测(P<0.05)。结论TCT检查联合HPV检测能够提高临床诊断的准确率,可在宫颈病变筛查中推广使用。

宫颈病变患者HR-HPV载量和调节性T淋巴细胞的表达及意义

目的 研究不同宫颈病变患者高危型人乳头瘤病毒(HR-HPV)载量和调节性T淋巴细胞(Treg)表达差异。方法 选取2021年3月至2023年9月江苏省常熟市中医院200例HR-HPV持续感染患者,分为宫颈上皮内瘤变(CIN)组、宫颈癌组及宫颈炎组,检测并比较3组宫颈分泌物中HPV-DNA和Treg细胞比例。结果 宫颈炎组、CIN组Ⅰ级、CIN组Ⅱ级、CIN组Ⅲ级及宫颈癌组患者HR-HPV感染阳性率、HR-HPV载量及Treg细胞比例差异均有统计学意义(均P <0.05)。CIN组Ⅲ级、宫颈癌组患者中不同HR-HPV载量组间Treg细胞比例差异均有统计学意义(均P <0.05)。CIN组Ⅲ级及宫颈癌组患者HR-HPV载量与Treg细胞呈明显正相关(均P <0.05)。结论 HR-HPV载量与宫颈病变程度有关,宫颈微环境中的Treg细胞与HR-HPV载量共同参与宫颈病变的发生发展。

宫颈脱落细胞特殊染色技术在宫颈病变筛查中的应用价值

目的:探讨宫颈脱落细胞特殊染色技术在宫颈病变筛查中的临床应用价值。方法:选取2022年8月-2023年5月在山东第二医科大学附属医院及潍坊市人民医院进行宫颈病变筛查的女性共2000例,所有对象均进行宫颈脱落细胞特殊染色技术(FRD)检测、人乳头瘤病毒(HPV)和液基薄层细胞(TCT)检测。3种筛查方法任一结果阳性病例行阴道镜检查,阴道镜下有病变者行宫颈活检。以宫颈组织病理结果为金标准,比较FRD、TCT、HPV、HPV+TCT组的检测效能及受试者工作特征曲线下面积(AUC)。结果:FRD检测灵敏度为83.8%、特异度为90.0%,Kappa值为0.618,AUC为0.869;TCT检测的灵敏度为65.1%、特异度为89.5%,Kappa值为0.485,AUC为0.773;HPV检测的灵敏度为94.6%、特异度为71.7%,Kappa值为0.387,AUC为0.832;HPV+TCT联合检测的灵敏度为98.9%、特异度为70.2%,Kappa值为0.391,AUC为0.846。结论:宫颈脱落细胞特殊染色试验用于宫颈病变筛查有较好的效果,可用于基层宫颈病变筛查。

叶酸受体介导的宫颈特殊染色联合人乳头瘤病毒快速检测筛查宫颈病变的临床效果分析

目的研究叶酸受体介导的宫颈特殊染色(FRD)联合人乳头瘤病毒快速检测(Care HPV)筛查宫颈病变的临床效果。方法本研究方法为回顾性分析,观察对象为2018年1月至2022年12月南京医科大学附属逸夫医院收治入院的90例宫颈病变患者,参考筛查方式分为研究组(n=45)与对照组(n=45)。研究组行FRD联合Care HPV筛查,对照组行薄层液基细胞学检查(TCT)联合Aptima HPV筛查。比较两组患者的检测效果、症状自评效果[焦虑自评量表(SAS)、抑郁自评量表(SDS)、症状自评量表(SCL-90)、生活质量量表(SF-36)]、社会经济效果及并发症(人工流产综合征、感染、出血)发生情况。结果两组患者的宫颈病变阳性检出率、阴性预测值、阳性预测值、特异度、敏感度、漏诊率比较,差异均无统计学意义(P>0.05)。两组患者的SCL-90、SF-36评分比较,差异均无统计学意义(P>0.05);研究组患者的SAS、SDS评分分别为(53.16±6.92)、(52.26±6.74)分,均明显低于对照组[(56.19±6.75)、(55.18±6.63)分],差异均有统计学意义(P<0.05)。研究组患者的检测时间为(6.19±1.32)min,明显长于对照组[(2.52±0.89)min],报告时间为(25.00±3.00)h,明显短于对照组[(71.00±11.00)h],检测费用为(59.00±20.00)元,明显低于对照组[(561.00±98.00)元],差异均有统计学意义(P<0.05)。两组患者人工流产综合征发生率比较,差异无统计学意义(P>0.05);研究组患者的感染、出血发生率分别为0、8.89%,均明显低于对照组(8.89%、28.89%),差异均有统计学意义(P<0.05)。结论FRD联合Care HPV筛查与TCT联合Aptima HPV筛查宫颈病变均具有显著效果,但FRD联合Care HPV筛查方案相较于TCT联合Aptima HPV筛查方案的报告时间更短,检测费用更少,患者症状自评效果更佳,并发症更少。

针对性护理在高危型人乳头瘤病毒检测及液基薄层细胞学检查中的作用

目的:分析针对性护理在高危型人乳头瘤病毒(HPV)检测和液基薄层细胞学检查中的作用。方法:选取2020年8月—2023年1月于上海交通大学医学院附属瑞金医院接受宫颈癌筛查的患者78例,按照随机数字表法分为对照组与研究组,各39例。对照组予以常规护理,研究组予以针对性护理。比较两组检查依从性、护理前后心理状态及护理满意度。结果:两组检查依从性比较,差异无统计学意义(P>0.05)。护理前,两组焦虑自评量表和抑郁自评量表评分比较,差异无统计学意义(P>0.05);护理后,两组焦虑自评量表和抑郁自评量表评分均低于护理前,且研究组低于对照组,差异有统计学意义(P<0.05)。研究组护理满意度高于对照组,差异有统计学意义(P=0.034)。结论:针对性护理能够有效地缓解接受高危型HPV和液基薄层细胞学检查患者的不良情绪,提高满意度。

HPV-23分型、TCT联合P16表达检测在宫颈病变筛查中的应用

目的探讨分析HPV-23分型、TCT联合P16表达检测在宫颈病变筛查中的应用。方法选取2022年6月—2023年6月在本院参加宫颈癌筛查的妇女200例为研究对象,进行HPV-23分型、TCT、P16表达检测,以病理学结果为金标准,计算HPV-23分型、TCT、P16单项检测和联合检测的诊断灵敏度、特异度。结果HPV-23分型检测结果显示阳性病例33例,阴性病例62例;TCT检测结果显示阳性病例35例,阴性病例72例;P16检测结果显示阳性病例19例,阴性病例115例;联合检测结果显示阳性病例48例,阴性病例139例。在诊断效能方面,HPV-23分型、TCT、P16单项检测以及联合检测的诊断灵敏度分别为62.26%、66.04%、35.85%及83.02%,而特异度则分别为42.18%、48.98%、78.23%及89.80%。经过对比分析,联合检测在灵敏度和特异度方面均表现出最高的效能(P<0.05)。结论HPV-23分型、TCT联合P16表达检测用于宫颈病变筛查中的价值较高,可作为首选筛查手段。

高危型HPV感染临床检验中实时荧光定量PCR检测法的作用

目的分析高危型人乳头瘤病毒(HPV)感染临床检验中实时荧光定量聚合酶链式反应(PCR)检测法的作用。方法选取80例疑似高危型HPV感染患者,均接受第二代杂交式捕获法(HCⅡ)、实时荧光定量PCR检测,以病理检查结果为金标准,分析实时荧光定量PCR检测价值。结果实时荧光定量PCR检验准确率97.50%、敏感度98.51%、特异度92.31%,均显著高于HCⅡ的78.75%、88.06%、38.46%(P<0.05);实时荧光定量PCR诊断检出率CINⅠ100%、慢性宫颈炎92.31%,均显著高于HCⅡ的88.10%、46.15%(P<0.05)。结论应用实时荧光定量PCR检测法可明显提高高危型HPV感染患者的临床检验准确性,提高治疗方法的针对性。